<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411372</url>
  </required_header>
  <id_info>
    <org_study_id>SCO105782</org_study_id>
    <nct_id>NCT00411372</nct_id>
  </id_info>
  <brief_title>Shortness Of Breath Questionnaire Validation Study</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group Study of Fluticasone Propionate/Salmeterol Combination (FSC 250/50mcg) Twice Daily and Salmeterol (SAL 50mcg) Twice Daily to Validate a New Shortness of Breath Questionnaire in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will last for approximately 8 weeks and will involve 4 visits. The study is being&#xD;
      carried out to validate a shortness of breath questionnaire&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subjects enrolled. Study was canceled before active&#xD;
  </why_stopped>
  <start_date>November 2006</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective of this study is the validation of the Shortness of Breath Questionnaire in subjects with COPD</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>spirometry (FEV1, FVC, IC)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diary card data</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Outcomes (Chronic Respiratory Questionnaire - SAS, Clinical Global Impression of Dyspnea Severity, Patient Global Assessment of Change Question, Clinical Global Impression of Change Question</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg</intervention_name>
    <other_name>fluticasone propionate/salmeterol 250/50mcg combination</other_name>
    <other_name>salmeterol 50mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of COPD&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or lactating.&#xD;
&#xD;
          -  Subjects with a primary diagnosis of asthma. (Subjects with a prior history of asthma&#xD;
             are eligible if COPD is currently their primary diagnosis)&#xD;
&#xD;
          -  Has a respiratory disorder other than COPD (e.g., bronchiectasis, sarcoidosis, active&#xD;
             tuberculosis, lung fibrosis), including subjects with a diagnosis of&#xD;
             alpha-1-antitrypsin deficiency.&#xD;
&#xD;
          -  Subjects with lung volume reduction surgery or lung transplant within the previous 12&#xD;
             months.&#xD;
&#xD;
          -  Chest X-ray (posterior-anterior) or CT scan reveals evidence of clinically significant&#xD;
             abnormalities not believed to be due to the presence of COPD. A chest X-ray must be&#xD;
             taken if the subject has not had one within 12 months of the Screening Visit.&#xD;
&#xD;
          -  Subjects with clinically significant cardiovascular (including clinically significant&#xD;
             ECG abnormalities, CHF), neurological, psychiatric, renal, immunological,&#xD;
             endocrine(including uncontrolled diabetes or thyroid disease) or hematological&#xD;
             abnormalities that is uncontrolled.&#xD;
&#xD;
          -  Subjects with carcinoma that has not been in complete remission for at least 5 years.&#xD;
             Carcinoma in situ of the cervix, squamous cell carcinoma of the skin and basal cell&#xD;
             carcinoma would not be considered exclusion criteria if the subject was considered&#xD;
             cured in less than 5 years since diagnosis.&#xD;
&#xD;
          -  Any adverse reaction including immediate or delayed hypersensitivity to any&#xD;
             betaagonist, sympathomimetic drug, or intranasal, inhaled, or oral corticosteroid&#xD;
             including any components of the formulations (e.g. lactose or milk protein).&#xD;
&#xD;
          -  Initiation of systemic beta-blocker medications at any time during the study. Systemic&#xD;
             beta-blockers and beta-blocker eye drops are allowed for those subjects who have been&#xD;
             on a stable regimen for at least 30 days prior to screening and judged capable to&#xD;
             continue this regimen until discharged from the study.&#xD;
&#xD;
          -  Subject continues on any prohibited medications, as listed in Section 5.6.2.&#xD;
&#xD;
          -  Subject is receiving treatment with long-term oxygen therapy (LTOT), defined as&#xD;
             inSection 5.6.2.&#xD;
&#xD;
          -  Use of immunosuppressive medications at any time during the study. Immunotherapy for&#xD;
             the treatment of allergies is allowed during the study provided that the subject has&#xD;
             received a constant dose for 30 days prior to the Screening Visit and the dose is&#xD;
             maintained during the study.&#xD;
&#xD;
          -  Subjects who are medically unable to withhold their albuterol or ipratropium for the 6&#xD;
             hour period required prior to administration of questionnaires and spirometry at each&#xD;
             study visit.&#xD;
&#xD;
          -  An infection of the upper or lower respiratory tract requiring treatment with&#xD;
             antibiotics 14 days prior to the Screening Visit.&#xD;
&#xD;
          -  Subjects who require nocturnal positive pressure.&#xD;
&#xD;
          -  Enrolled in or discontinuation of a pulmonary rehabilitation program within 30 days of&#xD;
             Visit 1. Subjects who are enrolled in a pulmonary rehabilitation program at study&#xD;
             start should maintain participation in the program for the duration of the study.&#xD;
&#xD;
          -  Use of any investigational drug within 30 days of Visit 1 or at any time during the&#xD;
             study is not allowed.&#xD;
&#xD;
          -  Subjects unable to comply with study procedures.&#xD;
&#xD;
          -  Study investigators, sub-investigators, study coordinators, employees of a&#xD;
             participating investigator or immediate family members of the aforementioned are&#xD;
             excluded from participation in this study.&#xD;
&#xD;
          -  Subjects with a history of psychiatric disease, intellectual deficiency, poor&#xD;
             motivation, substance abuse, (including drug and alcohol), or other conditions, which&#xD;
             will limit the validity of informed consent to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>December 13, 2006</study_first_submitted>
  <study_first_submitted_qc>December 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2006</study_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Questionnaire</keyword>
  <keyword>COPD</keyword>
  <keyword>Shortness of Breath</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone-Salmeterol Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

